Initiate ELEVATE-44-201 Phase 1/2 clinical study of ENTR-601-44
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 3 Feb 2025
- Due
- 30 Jun 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Company on track to initiate ELEVATE-44-201 in Q2 2025”
What we found
Evidence strength A What the grades mean
Entrada dosed the first patient in ELEVATE-44-201 during Q2 2025, as confirmed in its Q2 2025 earnings release, meeting the stated Q2 2025 initiation target.
-
A Entrada Therapeutics Reports Second Quarter 2025 Financial Results (8-K) States first patient dosed in ELEVATE-44-201, achieved in Q2 2025.
-
D Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201 Original commitment: on track to initiate ELEVATE-44-201 in Q2 2025.
-
D Entrada Therapeutics Reports First Quarter 2025 Financial Results Reaffirms on-track status and EU authorization received in Q1/Q2 2025.
Checked 12 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Language
- Firm (“will”, “on track to”)
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Entrada Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-TRDA-000096 · Corrections policy